IntegranGen (Paris: ALINT) specializes in transforming data from biological samples into diagnostic tools for oncology and genomic data. The company announced that the results of analysis of miR-31-3p expression in patients’ tumor samples had been published in Oncotarget. Bearing the title “Association between miR-31- 3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer”, the paper confirms the link between the efficacy of anti-EGFR treatment and miR-31-3p expression.
According to Prof. John Bridgewater, the study co-author and University College London Cancer Institute medical oncologist, the publication confirms that analyzing the expression levels of miR-31-3p RAS wild-type metastatic colorectal cancer patients can serve as a complementary diagnostic tool. The tool aids the identification of patients who may benefit from the targeted anti-EGFR therapy. He added that they are pleased with their ability to publish clinical information from the new trial which provides insight on the tailoring of therapeutic approaches. Prof. Bridgewater also serves as an investigator for the EPOC study.
IntegraGen’s Director of Molecular Diagnostics, Yann Gaston-Mathé, added that the peer-reviewed publications are part of the growing evidence on the significance of measuring miR-31-3p in tumors from metastatic colorectal cancer patients. The development is a milestone step towards the realization of the importance of precision medicine and generating coverage and adoption for miR-31-3p expression tests.
Oncotarget is a peer-reviewed open access medical journal that covers every research on oncology. Impact Journals publishes the weekly journal since its establishment in 2010. The editors in chief are Mikhail Blagosklonny and Andrei V. Gudkov. This journal has gained popularity due to its multiple constructive, punctual and insightful peer review that helps authors to improve the impact of their research.
Oncotarget’s mission is to ensure rapid and extensive availability of scientific results while maximizing the impact of research through insightful reviews. The journal also aims at eliminating the border between specialties and allowing discoveries to be shared efficiently. With the guidance of prominent scientist, the journal supports the contribution of researchers to the progress of science.